Delivery Order SPE2DR25D3104-SPE2DR26FE9EL
- Not listed
- The Defense Logistics Agency awarded a $1,577.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Guaifenesin-PSE ER 600-60 mg tablets (18-count). This competitively awarded, non-set-aside contract is scheduled for completion by December 11, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a relatively modest pharmaceutical procurement supporting federal...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Guaifenesin ER 600 mg tablets (500 count) with a ceiling value of $1,419.55. The contract was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This federal contract award is for the delivery of Guaifenesin-PSE ER 600-60 mg tablets to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $1,054.30 and a completion date of September 6, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a $29,550 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 200mg guaifenesin tablets. Under this order, Amerisourcebergen will deliver 100 bottles of the specified cough medication to a facility in Conshohocken, Pennsylvania by June 30, 2023 to support Department of Defense logistics operations. As a major pharmaceutical supplier, Amerisourcebergen frequently fulfills delivery orders for standard medical supplies through the DLA's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,610.76 for 500 tablets of Mucus Relief ER 600 mg, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with DLA....
- The Defense Logistics Agency awarded a $2,485.81 delivery order to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Mucinex D ER 600-60 mg tablets (18-count packages). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 16, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,171.29 to AmerisourceBergen Drug Corp for the supply of Mucus Relief ER 600 mg tablets (500-count units). This competitive, firm fixed-price contract is scheduled for completion by December 31, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under a larger contract vehicle supporting federal pharmaceutical procurement. This...
- The Defense Logistics Agency awarded a Firm Fixed Price delivery order valued at $1,383.61 to AmerisourceBergen Drug Corp for the supply of Mucus Relief DM ER 600-30 mg tablets (40 count). The award, issued on December 1, 2025, with completion expected by December 2, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order falls under...
- The Defense Logistics Agency awarded a $1,167.50 delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Mucinex D ER 600-60 mg tablets (36-count packages). This is a firm fixed price, competitively awarded delivery order with no set-aside designation, scheduled for ultimate completion on November 19, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 18, 2025, for the supply of Mucinex D ER 600-60 mg tablets (36-count packages) with a ceiling value of $3,390.15. This non-competitive, firm fixed-price delivery order is scheduled for completion by December 19, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a continuation of the company's critical role as a pharmaceutical supplier to...
- SPE2DR25D3104Indefinite Delivery Contract
- SPE2DR25D3104-SPE2DR26FE9ELDelivery Order
The Defense Logistics Agency awarded a $2,169.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Guaifenesin-PSE ER 600-60 mg tablets (18 count) on January 6, 2026, with completion scheduled for January 7, 2026. This non-set-aside award was performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order was issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 1/5/26 |